Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study.

"Conflicts of Interest The authors declare that they have no conflicts of interest."

"The study was funded through a contribution agreement with the University of British Columbia from the British Columbia Ministry of Health. We thank Tracey Hooper and Ellen Reynolds for presubmission editing assistance. The BC Ministry of Health approved access to and use of BC data facilitated by Population Data BC for this study. All inferences, opinions, and conclusions drawn in this manuscript are those of the authors and do not reflect the opinions or policies of the Data Stewards. British Columbia data sources were as follows (https://www2.gov.bc.ca/gov/content/health/conducting-health-research-evaluation/data-access-health-data-central): British Columbia Ministry of Health [creator] (2020): Medical Services Plan (MSP) Payment Information File. BC Ministry of Health [publisher]. MOH (2019); British Columbia Ministry of Health [creator] (2020): PharmaNet. BC Ministry of Health [publisher]. Data Stewardship Committee (2019); Canadian Institute for Health Information [creator] (2020): National Ambulatory Care Reporting System. BC Ministry of Health [publisher]. MOH (2019); Canadian Institute for Health Information [creator] (2020): Discharge Abstract Database (Hospital Separations). BC Ministry of Health [publisher]. MOH (2019); British Columbia Ministry of Health [creator] (2020): Consolidation File (MSP Registration & Premium Billing). BC Ministry of Health [publisher]. MOH (2019)."